Data for: Mixed-mode solid phase extraction combined with LC-MS/MS for determination of empagliflozin and linagliptin in human plasma
Description
This file contains three tables and three figures and all validation procedures followed in the study. Tale S1 Extraction recovery and matrix factors of empagliflozin and linagliptin from human plasma (n = 6) Table S2 Relative matrix effect in eight different lots of human plasma for empagliflozin and linagliptin Table S3 Stability of empagliflozin and linagliptin in plasma under various conditions (n = 6) Fig. S1. Post column analyte infusion MRM chromatograms for (a) empagliflozin (600 ng/mL) and empagliflozin-d4 (b) linagliptin (6 ng/mL) and linagliptin-d4. Fig. S2. Product ion mass spectra of (a) empagliflozin (m/z 451.3 → 71.1) & empagliflozin-d4 (m/z 455.3 → 71.1) and (b) linagliptin (m/z 473.2 → 420.2) & linagliptin-d4 (m/z 477.2 → 424.2) in the positive ionization mode. Fig. S3. Mean plasma concentration-time profiles of empagliflozin and linagliptin after administration of a single oral dose of 25 mg empagliflozin and 5 mg linagliptin fixed dose tablet formulation to 18 healthy Indian males under fasting and fed condition